Manfred Welslau, MD: Biosimilars and Patient Access

Transcript:

Perhaps, for the developing countries, biosimilars are a way to get more people on therapy. I’m thinking of China, thinking of India, thinking of Mexico and the Middle East countries. In these health systems, I think a lot of people are pending getting these medications, so this is a way to help people in these countries to be on therapy.